CapsoVision, Inc. (CV) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

CapsoVision, Inc. (CV) Healthcare & Pipeline Overview

CapsoVision, Inc. develops advanced medical technology, focusing on cutting-edge capsule endoscopy systems like CapsoCam Plus and CapsoCam Colon, complemented by AI-driven imaging platforms. The company specializes in minimally invasive gastrointestinal tract diagnosis, positioning itself within the evolving medical equipment and services sector.

What Is the Investment Thesis for CV?

CapsoVision, Inc. presents an investment profile centered on its specialized offerings in the growing minimally invasive gastrointestinal diagnostics market. The company's core value drivers include its innovative capsule endoscopy systems, CapsoCam Plus and CapsoCam Colon, and its advanced AI-driven imaging platforms, which address the increasing demand for less invasive diagnostic procedures. With a market capitalization of $295M, CapsoVision operates with a gross margin of 51.7%, indicating a strong pricing structure for its specialized products. However, the company currently faces significant financial challenges, evidenced by a profit margin of -198.9%, suggesting substantial operational costs relative to revenue. A beta of -2.79 indicates an inverse relationship with market movements, which is unusual and warrants close scrutiny regarding its underlying drivers. Key growth catalysts include the continued expansion of market share for its CapsoCam systems, particularly the adoption of CapsoCam Colon, and the further integration and commercialization of its AI platforms to enhance diagnostic capabilities. Investors should monitor the company's ability to navigate intense competition from established medical device manufacturers, improve its profitability metrics, and secure favorable reimbursement policies, which are critical for broader market penetration and financial sustainability.

Based on FMP financials and quantitative analysis

CV Key Highlights

CapsoVision, Inc. maintains a gross margin of 51.7%, reflecting strong product pricing power within its specialized medical technology niche.

• The company operates with a market capitalization of $295M, indicating its current valuation within the medical equipment and services sector.
• CapsoVision's profit margin stands at -198.9%, highlighting significant operational losses relative to its revenue generation.
• The company's beta of -2.79 suggests an unusual inverse correlation with overall market movements, which may be indicative of specific company-level factors or limited trading history.
• CapsoVision specializes in cutting-edge capsule endoscopy systems and AI-driven imaging platforms, addressing the increasing demand for minimally invasive gastrointestinal diagnostics.

Who Are CV's Competitors?

CV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CV's Key Strengths?

Specialization in innovative capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon).

• Integration of advanced AI-driven imaging platforms for enhanced diagnostics.
• Addresses the growing market demand for minimally invasive gastrointestinal diagnostic procedures.
• Strong gross margin of 51.7% indicates effective pricing for its specialized products.

What Are CV's Weaknesses?

Significant negative profit margin (-198.9%) suggests substantial operational losses and profitability challenges.

• Faces intense competition from established medical device manufacturers with broader product portfolios.
• Potentially limited product diversification compared to larger, more diversified healthcare companies.
• Unusual negative beta (-2.79) may indicate specific company-level risks or market perception.

What Could Drive CV Stock Higher?

CV catalyst: Increasing demand for less invasive diagnostic procedures in gastrointestinal health continues to drive interest and adoption of capsule endoscopy systems globally.

• Successful expansion of market share and clinical adoption for CapsoCam Plus in small bowel visualization, driven by positive clinical outcomes and physician preference.
• Effective commercialization and widespread adoption of CapsoCam Colon for colon examinations, potentially opening up a significant new revenue stream in colorectal screening.
• Further development and integration of AI-driven imaging platforms, enhancing diagnostic accuracy and efficiency, leading to stronger product differentiation and market appeal.
• Efforts to secure favorable reimbursement policies from payers and government bodies, which are crucial for broader market access and sustained growth of capsule endoscopy procedures.

What Are the Key Risks for CV?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 6 reported quarters.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Intense competition from established medical device manufacturers with broader product portfolios and larger sales and marketing infrastructures poses a significant challenge to market share growth.
• Inability to effectively expand market share for both CapsoCam Plus and CapsoCam Colon against entrenched competitors, limiting revenue growth and profitability.
• Challenges in securing favorable and consistent reimbursement policies for capsule endoscopy procedures, which could hinder adoption rates and impact the company's financial performance.
• The company's significant negative profit margin of -198.9% indicates ongoing operational losses, raising concerns about long-term financial sustainability without substantial improvements in profitability.
• Rapid technological obsolescence or slower-than-expected adoption of new AI-driven imaging platforms could diminish the competitive advantage of CapsoVision's offerings.

What Are the Growth Opportunities for CV?

• **Increasing Adoption of Minimally Invasive GI Diagnostics:** The global demand for minimally invasive diagnostic procedures continues to grow, driven by patient preference for reduced discomfort, shorter recovery times, and lower procedural risks compared to traditional invasive methods. CapsoVision's capsule endoscopy systems, CapsoCam Plus and CapsoCam Colon, are directly aligned with this trend. As healthcare systems increasingly prioritize patient-centric care and cost-efficiency, the adoption of such technologies is expected to expand. The market for capsule endoscopy is projected to see sustained growth, providing a fertile ground for CapsoVision to increase its market penetration and capitalize on this overarching industry shift over the next five to ten years.
• **Expansion and Commercialization of CapsoCam Colon:** While CapsoCam Plus addresses small bowel visualization, the development and commercialization of CapsoCam Colon represent a significant growth avenue by extending the benefits of capsule endoscopy to colon examinations. Colorectal cancer screening and diagnosis remain critical public health priorities, and a less invasive, patient-friendly option could substantially increase screening rates and early detection. Successfully establishing CapsoCam Colon in the market, securing favorable reimbursement, and demonstrating its clinical utility could unlock a substantial new revenue stream and significantly expand CapsoVision's total addressable market within the next three to seven years.
• **Leveraging AI-Driven Imaging Platforms:** CapsoVision's investment in advanced artificial intelligence-driven imaging platforms offers a distinct competitive advantage and a robust growth opportunity. AI can significantly enhance the efficiency and accuracy of analyzing the vast image data generated by capsule endoscopes, potentially reducing reading times for clinicians and improving the detection rate of subtle abnormalities. As AI technology matures and gains broader acceptance in clinical practice, CapsoVision's integrated AI solutions can differentiate its products, attract more users, and potentially lead to new service-based revenue models. This technological edge could drive market share gains and product stickiness over the medium to long term, within the next five to ten years.
• **Market Share Expansion in Small Bowel Capsule Endoscopy:** CapsoVision has established its presence with CapsoCam Plus for small bowel visualization. A key growth opportunity lies in aggressively expanding its market share within this segment. This involves continued product refinement, demonstrating superior clinical outcomes, enhancing user experience for gastroenterologists, and strategic marketing and sales initiatives. By capturing a larger portion of the existing small bowel capsule endoscopy market, CapsoVision can leverage its current product strengths and operational infrastructure. This organic growth strategy can yield tangible results in the near to medium term, within the next two to five years, by converting competitors' users and penetrating new clinical accounts.
• **Strategic Partnerships and Geographic Expansion:** While not explicitly detailed in the provided data, a common growth strategy for specialized medical technology firms involves strategic partnerships and geographic expansion. Collaborating with larger medical device distributors or healthcare providers can accelerate market access in new regions, particularly in international markets where regulatory pathways and distribution channels differ. Such partnerships could provide CapsoVision with the necessary resources and infrastructure to scale its operations and introduce its capsule endoscopy systems to a broader global patient base, thereby diversifying its revenue streams and reducing reliance on specific regional markets over the long term, within the next five to fifteen years.

What Threats Does CV Face?

• Intense competition from well-capitalized medical device companies with established market presence.
• Challenges in securing favorable reimbursement policies for new and existing capsule endoscopy technologies.
• Rapid technological advancements by competitors could lead to product obsolescence.
• Regulatory hurdles and compliance costs associated with medical device development and commercialization.

What Are CV's Competitive Advantages?

• Proprietary technology in capsule endoscopy systems, including CapsoCam Plus and CapsoCam Colon.
• Integration of advanced artificial intelligence (AI) for imaging analysis, potentially enhancing diagnostic accuracy and efficiency.
• Specialization in minimally invasive gastrointestinal diagnostics, addressing a specific and growing market need.
• Potential for patent protection on its cutting-edge capsule design and AI algorithms, creating barriers to entry.

What Does CV Do?

CapsoVision, Inc. operates as a dedicated medical technology firm, headquartered in Saratoga, US, with a workforce of 90 employees. The company's core mission revolves around pioneering innovative solutions for the diagnosis of various conditions within the gastrointestinal (GI) tract. At the heart of its product portfolio are advanced capsule endoscopy systems, designed to offer less invasive alternatives to traditional endoscopic procedures. Key offerings include CapsoCam Plus, which is primarily utilized for detailed visualization of the small bowel, and CapsoCam Colon, aimed at extending the benefits of capsule endoscopy to colon examinations. These systems represent a significant technological advancement, allowing for comprehensive internal imaging without the need for sedation or invasive scopes in many cases. Beyond hardware, CapsoVision distinguishes itself through its development of sophisticated artificial intelligence-driven imaging platforms. These AI capabilities are integrated to enhance the analysis of the vast amount of image data collected by the capsule endoscopes, potentially improving diagnostic accuracy and efficiency for healthcare professionals. The company's strategic focus is on addressing the growing demand for minimally invasive diagnostic procedures, a trend driven by patient preference for comfort and reduced procedural risks, as well as healthcare system efficiencies. While operating within a competitive landscape, CapsoVision's specialization in capsule endoscopy and its commitment to integrating AI position it as a focused innovator in the GI diagnostics segment of the broader medical equipment and services industry.

What Products and Services Does CV Offer?

• Develop and commercialize cutting-edge capsule endoscopy systems for gastrointestinal tract diagnosis.
• Offer CapsoCam Plus, a specialized capsule endoscope for visualizing the small bowel.
• Provide CapsoCam Colon, an innovative capsule endoscope designed for colon examinations.
• Integrate advanced artificial intelligence (AI)-driven imaging platforms to enhance diagnostic capabilities.
• Focus on creating minimally invasive diagnostic solutions for various GI conditions.
• Aim to improve patient comfort and reduce risks associated with traditional endoscopic procedures.
• Manufacture medical technology products for the healthcare sector.
• Contribute to the field of medical imaging with proprietary capsule technology.

How Does CV Make Money?

• Sells or leases its proprietary capsule endoscopy systems (hardware) to hospitals, clinics, and gastroenterology practices.
• Generates recurring revenue from the sale of single-use consumable capsule endoscopes required for each patient procedure.
• Potentially offers software licenses or service agreements for its AI-driven imaging platforms.
• Focuses on a business-to-business (B2B) model, targeting healthcare providers as its primary customers.

What Industry Does CV Operate In?

CapsoVision, Inc. operates within the dynamic and competitive Medical - Equipment & Services industry, specifically targeting the gastrointestinal (GI) diagnostics segment. This sector is characterized by continuous innovation, driven by advancements in imaging technology and a persistent demand for less invasive diagnostic and therapeutic procedures. The broader market trend favors technologies that enhance patient comfort, reduce procedural risks, and improve diagnostic accuracy and efficiency. CapsoVision's focus on capsule endoscopy systems, such as CapsoCam Plus and CapsoCam Colon, positions it directly within this trend, offering alternatives to traditional endoscopy. The company also leverages artificial intelligence, aligning with the industry-wide push towards AI integration for data analysis and clinical decision support. The competitive landscape includes established medical device manufacturers with extensive product portfolios and global distribution networks. CapsoVision's challenge and opportunity lie in expanding its market share and securing favorable reimbursement policies amidst this competitive environment, by demonstrating superior clinical outcomes and cost-effectiveness of its specialized GI visualization solutions.

Who Are CV's Key Customers?

• Hospitals and hospital networks seeking advanced GI diagnostic tools.
• Gastroenterology clinics and private practices performing endoscopic procedures.
• Medical imaging centers looking for minimally invasive diagnostic options.
• Healthcare professionals, including gastroenterologists and endoscopists, who utilize capsule endoscopy.

CapsoVision, Inc. Financial Trajectory

CapsoVision, Inc. (CV) reported $3.6M in revenue for Q2 2026, reflecting 30.5% growth compared to the prior quarter. The company recorded a net loss of $7.5M, with diluted EPS of $-0.15. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CV averaged $-0.20 in diluted EPS.

Company Profile

CapsoVision, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Saratoga, US. The company is led by CEO Kang-Huai Wang. CV has traded publicly since 2025.

How CapsoVision, Inc. Is Valued

CapsoVision, Inc. carries a market capitalization of $295M, placing it in the micro-cap category. Relative to its peer group, CV's quantitative score of 25/100 is below the peer average of 58/100.

Return on equity for CapsoVision, Inc. stands at 126.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -6.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.5%, the inverse of the P/E and a quick read on earnings relative to price.

CapsoVision, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 16.18 places it in the safe zone, indicating low near-term bankruptcy risk.

CapsoVision, Inc. has missed Wall Street's EPS estimate in 5 of its last 6 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 478.9% below estimates on average.

Wall Street analysts project CapsoVision, Inc. revenue of about $14.8M for fiscal 2026, with EPS near $-0.56.

CV Financials

CV Latest News

CV Analyst Consensus

CV MoonshotScore

CapsoVision, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources